The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients.

Elens, Laure;Bouamar, Rachida;Hesselink, Dennis A;Haufroid, Vincent;van Schaik, Ron H N;et.al.
(2012) Pharmacogenetics and Genomics — Vol. 22, n° 5, p. 373-380 (2012)

Files

095PharmacogeneticsandGenomics.pdf
  • Closed Access
  • Adobe PDF
  • 418.67 KB
Request a copy

Details

Authors
Show more
Abstract
Cyclosporine A (CsA) is a substrate of cytochrome P450 3A4 (CYP3A4). Recently, a newly discovered intron 6 single-nucleotide polymorphism in CYP3A4 (rs35599367 C>T), defining the CYP3A4*22 allele, has been linked to reduced hepatic expression and activity of CYP3A4. In the present study, the clinical impact of this single-nucleotide polymorphism was investigated in a cohort of patients receiving a CsA-based immunosuppressive regimen.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Elens, L., Bouamar, R., Hesselink, D. A., Haufroid, V., van Gelder, T., & van Schaik, R. H. N. (2012). The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenetics and Genomics, 22(5), 373-380. https://doi.org/10.1097/FPC.0b013e328351f3c1 (Original work published 2012)